Issue Code: MED
1,719
461
287
2025--2026
7 activities
CORNERSTONE GOVERNMENT AFFAIRS, INC.
116 activities
VAN SCOYOC ASSOCIATES
40 activities
BALLARD PARTNERS, LLC
38 activities
POWERS PYLES SUTTER & VERVILLE, P.C.
36 activities
THE CONAFAY GROUP, LLC
33 activities
ALSTON & BIRD LLP
31 activities
DLA PIPER LLP (US)
31 activities
CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
28 activities
FORBES-TATE
27 activities
CHECKMATE GOVERNMENT RELATIONS
25 activities
HOUSE OF REPRESENTATIVES
1,317 mentionsSENATE
1,307 mentionsHealth & Human Services, Dept of (HHS)
360 mentionsNatl Institutes of Health (NIH)
149 mentionsFood & Drug Administration (FDA)
141 mentionsCenters For Medicare and Medicaid Services (CMS)
135 mentionsDefense, Dept of (DOD)
121 mentionsWhite House Office
85 mentionsCenters For Disease Control & Prevention (CDC)
75 mentionsHealth Resources & Services Administration (HRSA)
61 mentionsSANA HEALTH
via TERRAPIN STRATEGY, INC
General Introductions
SAFT AMERICA
via BLUE TUSK COMMUNICATIONS
Met with members and staff to discuss issues surrounding database creation.
RED ONE MEDICAL
via BLUE TUSK COMMUNICATIONS
Worked with members of Congress and staff discussing issues related to medical procurement.
TRAVERE THERAPEUTICS
via THE HEALTH EQUITY STRATEGIES GROUP, LLC
Rare kidney disease
REPLIMUNE, INC.
via CHECKMATE GOVERNMENT RELATIONS
Issues related to FDA approval processes and procedures.
HOLY NAME MED CTR
via AWSOM ASSOC
Funding for GME programs and emergency departments
ATTERX BIOTHERAPEUTICS
via CAPSTONE NATIONAL PARTNERS
FY27 Appropriations
RARE ACCESS ACTION PROJECT
via COMMONWEALTH POLICY SOLUTIONS
Rare Disease education and advocacy, IRA and Orphan Cures Act
LILA SCIENCES, INC.
via MARBLE ARCH
Identify federal funding, policy, and legislative opportunities to support scientific superintelligence coupled with autonomous laboratory environments working in life, chemical, and material sciences.
BROAD INSTITUTE INC.
via BROAD INSTITUTE INC.
General education about biomedical research and support for scientific funding. Transparency of federal funding for medical research dollars, including indirect costs. Policies to advance AI supported long-term, population-scale health studies and accelerate translation of research findings to treatments. Federal funding for biomedical research, including research and policy issues related to biomarkers and stress biology, including potential applications in defense and human performance. Federal policies and investments related to data infrastructure and artificial intelligence for biomedical research, including standards for secure and scalable data ecosystems.